⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27752138 | 0.82 | — | — | |
| SCHEMBL26064924 | 0.79 | — | — | |
| SCHEMBL3124551 | 0.76 | — | — | |
| SCHEMBL523028 | 0.76 | — | — | |
| SCHEMBL1115312 | 0.76 | — | — | |
| SCHEMBL24630408 | 0.76 | — | — | |
| SCHEMBL2032383 | 0.76 | — | — | |
| SCHEMBL6772856 | 0.76 | — | — | |
| SCHEMBL523027 | 0.76 | — | — | |
| SCHEMBL24718815 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| US-12281116-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604287-A | Heterocyclic PAD4 inhibitors | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-115348961-B | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-4433471-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118510769-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11584755-B2 | Dihydrothieno[3,2-b]pyridine compounds | IDEAYA BIOSCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4103559-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115348961-A | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021163254-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019067442-A1 | DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |